FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361950948> ?p ?o ?g. }

• W4361950948 abstract "<div>Abstract<p><b>Purpose:</b> To evaluate the safety and pharmacokinetics of siltuximab, an anti–interleukin-6 chimeric monoclonal antibody (mAb) in patients with B-cell non-Hodgkin lymphoma (NHL), multiple myeloma, or Castleman disease.</p><p><b>Experimental Design:</b> In an open-label, dose-finding, 7 cohort, phase I study, patients with NHL, multiple myeloma, or symptomatic Castleman disease received siltuximab 3, 6, 9, or 12 mg/kg weekly, every 2 weeks, or every 3 weeks. Response was assessed in all disease types. Clinical benefit response (CBR; composite of hemoglobin, fatigue, anorexia, fever/night sweats, weight, largest lymph node size) was also evaluated in Castleman disease.</p><p><b>Results:</b> Sixty-seven patients received a median of 16 siltuximab doses for a median of 8.5 (maximum 60.5) months; 29 were treated 1 year or longer. There was no dose-limiting toxicity, antibodies to siltuximab, or apparent dose–toxicity relationship. The most frequently reported possible drug-related adverse events were thrombocytopenia (25%), hypertriglyceridemia (19%), neutropenia (19%), leukopenia (18%), hypercholesterolemia (15%), and anemia (10%). None of these events led to dose delay/discontinuation except for neutropenia and thrombocytopenia (<i>n</i> = 1 each). No treatment-related deaths occurred. C-reactive protein (CRP) suppression was most pronounced at 12 mg/kg every 3 weeks. Mean terminal-phase half-life of siltuximab ranged 17.73 to 20.64 days. Thirty-two of 37 (86%) patients with Castleman disease improved in 1 or more CBR component; 12 of 36 evaluable Castleman disease patients had radiologic response [complete response (CR), <i>n</i> = 1; partial response (PR), <i>n</i> = 11], including 8 of 19 treated with 12 mg/kg; 2 of 14 (14%) evaluable NHL patients had PR; 2 of 13 (15%) patients with multiple myeloma had CR.</p><p><b>Conclusion:</b> No dose-related or cumulative toxicity was apparent across all disease indications. A dose of 12 mg/kg every 3 weeks was recommended on the basis of the high response rates in Castleman disease and the sustained CRP suppression. Randomized studies are ongoing in Castleman disease and multiple myeloma. <i>Clin Cancer Res; 19(13); 3659–70. ©2013 AACR</i>.</p></div>" @default.
• W4361950948 created "2023-04-05" @default.
• W4361950948 creator A5000725082 @default.
• W4361950948 creator A5009378735 @default.
• W4361950948 creator A5012061864 @default.
• W4361950948 creator A5013974745 @default.
• W4361950948 creator A5023276777 @default.
• W4361950948 creator A5024385519 @default.
• W4361950948 creator A5028046297 @default.
• W4361950948 creator A5028677309 @default.
• W4361950948 creator A5037214066 @default.
• W4361950948 creator A5049970120 @default.
• W4361950948 creator A5053481267 @default.
• W4361950948 creator A5059874786 @default.
• W4361950948 creator A5069409328 @default.
• W4361950948 creator A5071438752 @default.
• W4361950948 creator A5085370688 @default.
• W4361950948 creator A5086005303 @default.
• W4361950948 creator A5090044223 @default.
• W4361950948 date "2023-03-31" @default.
• W4361950948 modified "2023-10-01" @default.
• W4361950948 title "Data from A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease" @default.
• W4361950948 doi "https://doi.org/10.1158/1078-0432.c.6522105.v1" @default.
• W4361950948 hasPublicationYear "2023" @default.
• W4361950948 type Work @default.
• W4361950948 citedByCount "0" @default.
• W4361950948 crossrefType "posted-content" @default.
• W4361950948 hasAuthorship W4361950948A5000725082 @default.
• W4361950948 hasAuthorship W4361950948A5009378735 @default.
• W4361950948 hasAuthorship W4361950948A5012061864 @default.
• W4361950948 hasAuthorship W4361950948A5013974745 @default.
• W4361950948 hasAuthorship W4361950948A5023276777 @default.
• W4361950948 hasAuthorship W4361950948A5024385519 @default.
• W4361950948 hasAuthorship W4361950948A5028046297 @default.
• W4361950948 hasAuthorship W4361950948A5028677309 @default.
• W4361950948 hasAuthorship W4361950948A5037214066 @default.
• W4361950948 hasAuthorship W4361950948A5049970120 @default.
• W4361950948 hasAuthorship W4361950948A5053481267 @default.
• W4361950948 hasAuthorship W4361950948A5059874786 @default.
• W4361950948 hasAuthorship W4361950948A5069409328 @default.
• W4361950948 hasAuthorship W4361950948A5071438752 @default.
• W4361950948 hasAuthorship W4361950948A5085370688 @default.
• W4361950948 hasAuthorship W4361950948A5086005303 @default.
• W4361950948 hasAuthorship W4361950948A5090044223 @default.
• W4361950948 hasConcept C126322002 @default.
• W4361950948 hasConcept C2776364478 @default.
• W4361950948 hasConcept C2777063308 @default.
• W4361950948 hasConcept C2778248108 @default.
• W4361950948 hasConcept C2780873365 @default.
• W4361950948 hasConcept C29730261 @default.
• W4361950948 hasConcept C71924100 @default.
• W4361950948 hasConcept C90924648 @default.
• W4361950948 hasConceptScore W4361950948C126322002 @default.
• W4361950948 hasConceptScore W4361950948C2776364478 @default.
• W4361950948 hasConceptScore W4361950948C2777063308 @default.
• W4361950948 hasConceptScore W4361950948C2778248108 @default.
• W4361950948 hasConceptScore W4361950948C2780873365 @default.
• W4361950948 hasConceptScore W4361950948C29730261 @default.
• W4361950948 hasConceptScore W4361950948C71924100 @default.
• W4361950948 hasConceptScore W4361950948C90924648 @default.
• W4361950948 hasLocation W43619509481 @default.
• W4361950948 hasOpenAccess W4361950948 @default.
• W4361950948 hasPrimaryLocation W43619509481 @default.
• W4361950948 hasRelatedWork W1835795335 @default.
• W4361950948 hasRelatedWork W1863366310 @default.
• W4361950948 hasRelatedWork W1981507940 @default.
• W4361950948 hasRelatedWork W1994300152 @default.
• W4361950948 hasRelatedWork W2002655750 @default.
• W4361950948 hasRelatedWork W2299454531 @default.
• W4361950948 hasRelatedWork W2414718431 @default.
• W4361950948 hasRelatedWork W3154690958 @default.
• W4361950948 hasRelatedWork W3214690284 @default.
• W4361950948 hasRelatedWork W4283783635 @default.
• W4361950948 isParatext "false" @default.
• W4361950948 isRetracted "false" @default.
• W4361950948 workType "article" @default.